Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review.
ESC Heart Fail
; 10(4): 2718-2721, 2023 08.
Article
in En
| MEDLINE
| ID: mdl-37313579
ABSTRACT
Pulmonary arterial hypertension-targeted therapies in portopulmonary hypertension (PoPH) are scarce, let alone for patients with chronic liver failure (CLF) and hepatopulmonary syndrome (HPS). A 48-year male was admitted to the hospital because of cirrhosis for 18 years, systemic oedema, and chest distress after exercise for 1 week. He was diagnosed with CLF, PoPH, and HPS. After 7 weeks of macitentan treatment, the patient's activity tolerance, pulmonary artery systolic pressure, arterial partial pressure of oxygen (PaO2 ), cTNI, and NT-proBNP changes indicated gradual recovery, without hepatic safety concerns. This case indicated that administering macitentan in patients diagnosed as PoPH (with CLF and HPS) may be efficient and safe enough in a clinical setting.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hepatopulmonary Syndrome
/
Pulmonary Arterial Hypertension
/
Hypertension, Portal
/
Hypertension, Pulmonary
Type of study:
Diagnostic_studies
Limits:
Humans
/
Male
Language:
En
Journal:
ESC Heart Fail
Year:
2023
Document type:
Article
Affiliation country: